Mesa Laboratories, Inc. Q1 FY2027 earnings call

• CEO 100-Day Review & Strategic Direction

  • New CEO Siddhartha Kadia's core thesis: Mesa holds durable, regulation-embedded franchises with growing earnings power, and all current issues are fixable execution problems.
  • Near-term priority is organic execution on existing businesses and active portfolio management, not large acquisitions. Small tuck-ins or distributor buyouts may occur in the second half of the fiscal year.
  • Portfolio is evaluated based on returns, margin profile, and strategic fit; core franchises (SDC, BPD, Calibration Solutions) will receive investment, while Clinical Genomics is managed deliberately for cost and returns.
  • New growth-oriented customer-centric culture with faster decision-making and disciplined capital reallocation to high-return opportunities is being implemented.

• Operational Updates by Franchise

  • BPD: The 5% Q1 growth follows a 30% decline last quarter, partially due to easier comparisons and catch-up of deferred orders held up by export controls. A new general manager has been hired to rebuild the commercial team and processes, with full implementation expected over the next year. R&D has been reprioritized to accelerate the launch of the next-generation Gyrolab platform, now scheduled for fiscal 2028. Management expects full-year BPD growth.
  • SDC: Q1 revenue decline stems from internal delivery reliability issues, not weak demand. Demand remains healthy, with a substantial order book and 5% TTM revenue growth. Past due backlog rose ~$1 million from year-end lows (though still well below 2026 peaks) after a Q4 2026 surge reduced backlog by two-thirds, because improvements were not locked into permanent processes. The operations SVP has been assigned to prioritize permanent process fixes to reduce production variability without loosening quality standards; management will provide a clear progress update in November. Extended delivery delays risk customer churn, which adds urgency to the fix.
  • Calibration Solutions: Delivered steady 7.6% growth as expected, providing stable recurring revenue to the portfolio.
  • Clinical Genomics: Q1 performance was in-line with expectations. China revenue declined 7% (a slower pace of decline than last year, as previously guided), while ex-China revenue grew 0.6%. The business continues to be managed for cost structure and returns.

• Financial Performance

  • GAAP operating income increased 129% YoY to $7 million. Non-GAAP adjusted operating income (AOI) increased 16.5% YoY to $15 million; excluding a $382,000 legal settlement, AOI increased 19.5% to $15.4 million (25.6% of revenue, a 390 bps margin expansion).
  • TTM AOI excluding unusual items is ~$66 million, up $2.5 million from the end of fiscal 2026.
  • $8.7 million of debt was repaid in Q1, bringing the net leverage ratio to 1.85x. Operating cash flow increased $12.8 million YoY to $14.7 million driven by improved collections and operating performance.

Total consolidated Q1 2027 revenue was $60.1 million, 1% year-over-year (YoY) organic growth, with 0.4% core organic growth after excluding 60 bps of currency tailwind. Segments:

1. Sterilization and Disinfection Controls (SDC): Revenue of $24.5 million, 3.6% organic YoY decline, representing 41% of total Q1 revenue. Gross margin decreased 150 bps due to lower volume on a partially fixed cost base. On a trailing 12-month (TTM) basis, SDC revenue is ~$101 million, up 5% YoY.
2. Biopharmaceutical Development (BPD): Revenue of $12.1 million, 5% organic YoY growth. Gross margin increased 800 bps driven by a higher mix of higher-margin consumables, supply chain efficiencies, and operating leverage from revenue growth.
3. Calibration Solutions: Revenue of $13.3 million, 7.6% organic YoY growth, representing ~22.1% of total Q1 revenue. Gross margin increased 350 bps due to higher revenue on a partially fixed cost base.
4. Clinical Genomics: Revenue of $10.3 million, essentially flat (-0.1%) YoY, representing ~17.1% of total Q1 revenue. Gross margin increased 790 bps driven by price improvements and manufacturing/supply chain efficiency gains.

• Full year fiscal 2027 guidance will be released alongside first half 2027 results at the November 2027 earnings call, to ensure guidance is informed by half a year of operating data under the new leadership and operational changes. • Q1 2027 trends are consistent with internal planning, and the company returned to positive core organic growth as expected in May 2026. • Net leverage is targeted to reach the 1.5x to 1.75x range by the end of fiscal 2027, with continued deleveraging on track.

• Delivery reliability issues at SDC could lead existing customers to evaluate alternative suppliers, resulting in permanent lost revenue. • Export control processing continues to create delays for certain BPD orders, creating quarterly revenue volatility. • Unrealized currency gains/losses on an outstanding intercompany loan will continue to create quarter-to-quarter volatility in non-operating income/expense. • Actual future results may differ materially from forward-looking statements due to risks including: weak market acceptance of new products, failure to execute strategic/operational initiatives, manufacturing/fulfillment/supply chain disruptions, changing customer purchasing patterns, regulatory changes, unexpected capital allocation impacts, changes to expected tax rates, and weak global or national economic conditions.

Q: Historically Mesa has focused on M&A activity; which portions of the business are the easiest to build upon, what is the state of liquidity, and have market conditions eased in China?

A: Three of Mesa's four core businesses have strong growth and margin profiles, with additional capital and management mindshare currently being reallocated to SDC, BPD, and Calibration Solutions. Current net leverage is 1.85x with an effective 5.6% interest rate, and liquidity is sufficient to continue deleveraging toward the 1.5x-1.75x target. China has ongoing structural market headwinds, but Mesa's China exposure has declined significantly over the past two years to a very small share of total revenue, so broader headwinds have limited impact on overall results.

Q: What is the focus of execution fixes, are there associated costs, and what is the expected market growth context for upcoming November guidance?

A: No color on full guidance or market growth projections will be provided ahead of the November release, as this work is still ongoing. Key execution fixes include targeted talent changes (such as the new BPD general manager), dedicating senior operations leadership to fix SDC delivery issues, and adding a sense of urgency and disciplined capital reallocation to the existing strong quality culture, with a new focus on growth and customer loyalty. All resource reallocation is happening within existing operational scope.

Q: What was the magnitude of the SDC fulfillment headwind in Q1, and what is the cadence for recovering this delayed revenue?

A: The SDC headwind from delivery delays resulted in a $1 million increase in past due backlog from Q4 2026 year-end lows. Consistent with management's overall framing, SDC performance is best measured on a 12-month trailing basis, which still shows 5% YoY growth. Management will continue to work to clear backlog as quickly as possible, but no specific timeframe for full recovery was provided, with a full update to come in the November earnings call.